Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15539753 | 0.82 | ATAD2 (0.38) | — | |
| SCHEMBL29767278 | 0.77 | HCAR2 (0.50) | HCAR2 | |
| SCHEMBL7648929 | 0.73 | KDM4E (0.54) | DUT | |
| SCHEMBL27243730 | 0.72 | KDM4E (0.41) | — | |
| SCHEMBL356483 | 0.72 | TYMP (0.49) | HCAR2 | |
| SCHEMBL5946187 | 0.71 | SLC6A4 (0.52) | — | |
| SCHEMBL4353311 | 0.71 | DPYD (0.50) | — | |
| SCHEMBL357910 | 0.71 | TYMP (0.50) | HCAR2 | |
| SCHEMBL23610067 | 0.69 | GAA (0.47) | — | |
| SCHEMBL17991909 | 0.69 | HTT (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11518779-B2 | Inhibitors of DNMT1 as anticancer therapeutic agents | VICTORIA LINK LIMITED (NZ) | 2022-12-06 | — | — | US | disclosed |
| US-11518779-B2 | Inhibitors of DNMT1 as anticancer therapeutic agents | VICTORIA LINK LIMITED (NZ) | 2022-12-06 | — | — | US | disclosed |
| US-20210206795-A1 | INHIBITORS OF DNMT1 AS ANTICANCER THERAPEUTIC AGENTS | VICTORIA LINK LTD (NZ) | 2021-07-08 | — | — | US | disclosed |
| US-20210206795-A1 | INHIBITORS OF DNMT1 AS ANTICANCER THERAPEUTIC AGENTS | VICTORIA LINK LTD (NZ) | 2021-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11518779-B2 | Inhibitors of DNMT1 as anticancer therapeutic agents | DNMT1, DNMT3A, DNMT3B | DUT 152/4885HCAR2 4587/4885 |
| US-20210206795-A1 | INHIBITORS OF DNMT1 AS ANTICANCER THERAPEUTIC AGENTS | DNMT1, DNMT3B, DNMT3A | DUT 158/4885HCAR2 4577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.